data from 17 of the 19 individuals enrolled in our phase ib/iia trial in the united kingdom who were treated systemically with eteplirsen demonstrated some generation of novel dystrophin , and one participant exhibited the first ever reported increase in dystrophin positive muscle fibers to 55 % of normal . restoration of dystrophin expression and dystrophin positive fibers is believed to be critical for successful disease-modifying treatment of individuals with dmd . we initiated a phase iib trial for eteplirsen in august 2011 with an objective of initiating a pivotal trial by the end of 2012. we anticipate releasing results from our current phase iib trial by the end of april 2012. we are also leveraging the capabilities of our rna-based technology platforms to develop therapeutics for the treatment of infectious diseases . the u.s. department of defense , or dod , has provided significant financial support for the development of therapeutics against ebola , marburg , dengue and influenza viruses , as described in greater detail below . the basis for our novel rna-based therapeutics is our phosphorodiamidate-linked morpholino oligomer , or pmo , chemistries . unlike other rna-based therapeutics , which are often used to down-regulate gene expression , our technologies can be used to selectively up-regulate or down-regulate the production of a target protein , or direct the expression of novel proteins involved in human diseases and disorders . we believe that these broad capabilities represent highly competitive rna-based technology platforms and a strong intellectual property position , which we are leveraging to identify additional product candidates and explore various strategic opportunities . as of february 29 , 2012 , we owned or controlled approximately 276 u.s. and corresponding foreign patents and 191 u.s. and corresponding foreign patent applications . since our inception in 1980 , we have incurred losses of approximately $ 310.0 million and substantially all of our revenue has been derived from research and development contracts with the u.s. government . we have not yet generated any material revenue from product sales and we have incurred expenses related to research and development , general and administrative charges and acquired in-process research and development resulting from two acquisitions . we expect to continue to incur losses in the future as we continue our research and development efforts and seek approval from various regulatory agencies for our product candidates , but there can be no assurance that we will obtain approval for our product candidates and achieve revenues from product sales . -45- in march 2008 , we acquired all of the stock of ercole biotechnology , inc. , or ercole , in exchange for 5,811,721 shares of our common stock , which was valued at approximately $ 8.4 million , and the assumption of approximately $ 1.8 million in liabilities of ercole . we also issued warrants to purchase our common stock ( also classified as equity ) , which were valued at $ 437,000 , in exchange for certain outstanding warrants issued by ercole . in december 2011 , we restructured our operations by reducing our workforce by 35 employees , or 28 % . restructuring charges totaling $ 1.1 million were recorded in 2011 and included severance and related costs . the charge included approximately $ 0.5 million to research and development expense and approximately $ 0.6 million to general and administrative expense . the restructuring was completed by january 31 , 2012 and all severance costs are expected to be paid by july 31 , 2012. as of december 31 , 2011 , we had cash and cash equivalents of $ 39.9 million and we anticipate receiving continued funding from the u.s. government to pursue the development of our therapeutics against ebola and marburg . combined together , we believe these sources provide us with sufficient cash to fund operations at least through the following 12 months . in addition , we are likely to pursue additional funding through public or private financings and cash generated from establishing collaborations or licensing our technology to other companies . should our funding from the u.s. government cease or be delayed , it would have a significant negative impact on our financial condition and on this guidance and we would likely be forced to significantly curtail our research and development efforts . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with u.s. government sponsored programs , and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenues or profitable operations . u.s. government contracts in the periods presented , nearly all of the revenue we generated was derived from research contracts with and grants from the u.s. government . as of december 31 , 2011 , we had substantially completed all of our contracts with the u.s. government except for the july 2010 agreement for the development of therapeutics against ebola and marburg . pursuant to this agreement , as of december 31 , 2011 , we are currently entitled to receive up to $ 126.5 million of which $ 52.7 million has been recognized as revenue . in addition , if the u.s. government elects to exercise all its options under the agreement , an additional $ 161.5 million in funding is available . the following table sets forth the revenue from each of our contracts with the u.s. government and other revenue for the years ended december 31 , 2011 , 2010 and 2009. replace_table_token_5_th -46- the following is a description of each of our significant u.s. government contracts and grants . story_separator_special_tag million or decreased up to $ 1.0 million , respectively , with such difference reflected in our statement of operations . see note 9warrants of the audited financial statements included elsewhere in this annual report on form 10-k for a further discussion of warrants . results of operations for the years ended december 31 , 2011 , 2010 and 2009 the following table sets forth selected consolidated statements of operations data for each of the periods indicated : summary of results for fiscal years 2011 , 2010 and 2009 replace_table_token_8_th -51- revenue revenue for 2011 increased by $ 17.6 million , or 60 % , compared to 2010. the increase was primarily due to the 2010 ebola and marburg contract we received in july 2010 , which contributed revenue of $ 42.9 million in 2011 , an increase of $ 33.1 million over the prior year . this increase was partially offset by decreases in revenue on contracts we completed during 2011 , including $ 10.0 million from the may 2009 and june 2010 h1n1 agreements , $ 1.2 million from the qtdp grants and a $ 3.7 million decrease for the 2006 ebola , marburg and junín contracts . revenue for 2010 increased by $ 11.8 million , or 67 % , compared to 2009 due to the increase from the ebola and marburg contract of $ 9.8 million , increases in revenue from the h1n1 contracts of $ 12.3 million , and an increase of $ 1.2 million from the qtdp grants . these increases were partially offset by a $ 9.1 million decrease in revenue from the 2006 ebola , marburg and junín contract and a $ 2.4 million decrease in children 's national medical center contract related to dmd . research and development expenses research and development expenses for 2011 increased by $ 30.9 million , or 86 % , compared to 2010 due primarily to a $ 22.8 million increase in costs related to the july 2010 ebola and marburg contract , a $ 6.4 million increase in costs for our proprietary dmd program that is in phase ii clinical trials , a $ 4.8 million increase for proprietary research and development and a $ 3.9 million increase from manufacturing activities . these increases were partially offset by a $ 5.0 million decrease in costs related to the h1n1 contracts completed in 2011 and a $ 2.0 million decrease related to the 2006 ebola , marburg and junín contract , which was substantially completed in 2010. research and development expenses for 2010 increased by $ 11.6 million , or 47 % , compared to 2009 due primarily to a $ 5.6 million increase in costs related to the july 2010 ebola and marburg contract and a $ 4.2 million increase in costs related to the june 2010 h1n1 government contract . both of these contracts were new in 2010. additionally , overall research and development spending increased by $ 4.6 million and expenditures on the 2009 h1n1 government contract increased $ 1.5 million . these increases were offset by a $ 4.3 million decline in spending related to the 2006 ebola , marburg and junín contracts . general and administrative expenses general and administrative expenses for 2011 increased by $ 1.7 million , or 12 % , compared to 2010. this increase was due primarily to an increase of $ 1.4 million in personnel related costs and $ 1.1 million in professional consulting costs . legal fees and employee severance costs decreased by approximately $ 0.5 million each while facility costs also increased by $ 0.2 million . general and administrative expenses for 2010 increased by $ 5.7 million , or 65 % , compared to 2009. this significant increase in 2010 was due to $ 2.6 million in severance costs and stock compensation expense related to the departure in april 2010 of our former chief executive officer and an increase of $ 2.0 million in employee costs due to the july 2010 ebola and marburg contract and the h1n1 contracts . other increases included legal costs of $ 0.9 million , facilities expense of $ 0.4 million for the addition of our new bothell , washington facilities , and a $ 0.4 million loss on the write down of the property held for sale . these increases were partially offset by a $ 0.6 million decrease in professional consulting costs . interest income ( expense ) and other , net the increase in interest income ( expense ) and other , net for 2011 compared to 2010 was primarily due to increased interest income on invested cash . the increase in interest income ( expense ) and other , net for 2010 compared to 2009 was attributable to increased interest income on invested cash of $ 0.1 million and $ 0.1 million from increased rental income from -52- the sublease of excess space in our corvallis , oregon facility . additionally , these increases in income were offset by decreases of $ 0.5 million in patent abandonments and impairment of property held for sale that occurred in 2009. decrease ( increase ) on warrant valuation in 2011 , we recognized $ 33.0 million of other income due to the reduction in the fair value of our outstanding warrants that are classified as liabilities on our consolidated balance sheet . in 2010 , we recognized $ 11.5 million of other expense due to the increase in the fair value of the outstanding warrants on our consolidated balance sheet . the change in fair value of our warrant liability is primarily attributable to the change in our stock price . net loss the decrease in net loss of $ 29.9 million , or 93 % , for 2011 compared to 2010 was primarily attributable to a $ 44.9 million increase in other income resulting from a decrease in the fair value of our outstanding warrants offset by an increase in operating loss of $ 15.0 million

liquidity and capital resources at december 31 , 2011 , cash and cash equivalents were $ 39.9 million , compared to $ 33.6 million at december 31 , 2010. our principal sources of liquidity are revenue from our u.s. government research contracts and grants and equity financings . our principal uses of cash are research and development expenses , general and administrative expenses and other working capital requirements . based on the factors described below , we believe that our currently available cash and cash equivalents along with the anticipated receipt of future proceeds pursuant to the funded portion of our existing contracts with the u.s. government are sufficient to finance our operations for at least the next 12 months . sources of funds our primary source of revenue is from development of product candidates pursuant to our contracts with the u.s. government . government funding is subject to the u.s. government 's appropriations process and the u.s. government has the right under our contracts with them to terminate such contracts for convenience . if u.s. government funding is not received or is delayed , our results of operations would be materially and adversely affected and we may need to seek additional sources of capital and significantly curtail our research and development activities . we do not generate any revenue from non-government , commercial sale of our pharmaceutical product candidates . in january 2009 , we sold approximately 14.2 million shares of our common stock and also issued warrants to purchase approximately 14.2 million shares of our common stock in an offering registered under the securities act of 1933 , or the securities act . the offering generated net proceeds of approximately $ 15.5 million . the warrants issued to the investors in the offering have an exercise price of $ 1.16 per share and are exercisable at any time on or before july 30 , 2014. in connection with the offering , we also issued to the placement agent a warrant to purchase approximately 427,000 shares of our common stock at an exercise price of $ 1.45 per share .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources at december 31 , 2011 , cash and cash equivalents were $ 39.9 million , compared to $ 33.6 million at december 31 , 2010. our principal sources of liquidity are revenue from our u.s. government research contracts and grants and equity financings . our principal uses of cash are research and development expenses , general and administrative expenses and other working capital requirements . based on the factors described below , we believe that our currently available cash and cash equivalents along with the anticipated receipt of future proceeds pursuant to the funded portion of our existing contracts with the u.s. government are sufficient to finance our operations for at least the next 12 months . sources of funds our primary source of revenue is from development of product candidates pursuant to our contracts with the u.s. government . government funding is subject to the u.s. government 's appropriations process and the u.s. government has the right under our contracts with them to terminate such contracts for convenience . if u.s. government funding is not received or is delayed , our results of operations would be materially and adversely affected and we may need to seek additional sources of capital and significantly curtail our research and development activities . we do not generate any revenue from non-government , commercial sale of our pharmaceutical product candidates . in january 2009 , we sold approximately 14.2 million shares of our common stock and also issued warrants to purchase approximately 14.2 million shares of our common stock in an offering registered under the securities act of 1933 , or the securities act . the offering generated net proceeds of approximately $ 15.5 million . the warrants issued to the investors in the offering have an exercise price of $ 1.16 per share and are exercisable at any time on or before july 30 , 2014. in connection with the offering , we also issued to the placement agent a warrant to purchase approximately 427,000 shares of our common stock at an exercise price of $ 1.45 per share .
```    
 Suspicious Activity Report : data from 17 of the 19 individuals enrolled in our phase ib/iia trial in the united kingdom who were treated systemically with eteplirsen demonstrated some generation of novel dystrophin , and one participant exhibited the first ever reported increase in dystrophin positive muscle fibers to 55 % of normal . restoration of dystrophin expression and dystrophin positive fibers is believed to be critical for successful disease-modifying treatment of individuals with dmd . we initiated a phase iib trial for eteplirsen in august 2011 with an objective of initiating a pivotal trial by the end of 2012. we anticipate releasing results from our current phase iib trial by the end of april 2012. we are also leveraging the capabilities of our rna-based technology platforms to develop therapeutics for the treatment of infectious diseases . the u.s. department of defense , or dod , has provided significant financial support for the development of therapeutics against ebola , marburg , dengue and influenza viruses , as described in greater detail below . the basis for our novel rna-based therapeutics is our phosphorodiamidate-linked morpholino oligomer , or pmo , chemistries . unlike other rna-based therapeutics , which are often used to down-regulate gene expression , our technologies can be used to selectively up-regulate or down-regulate the production of a target protein , or direct the expression of novel proteins involved in human diseases and disorders . we believe that these broad capabilities represent highly competitive rna-based technology platforms and a strong intellectual property position , which we are leveraging to identify additional product candidates and explore various strategic opportunities . as of february 29 , 2012 , we owned or controlled approximately 276 u.s. and corresponding foreign patents and 191 u.s. and corresponding foreign patent applications . since our inception in 1980 , we have incurred losses of approximately $ 310.0 million and substantially all of our revenue has been derived from research and development contracts with the u.s. government . we have not yet generated any material revenue from product sales and we have incurred expenses related to research and development , general and administrative charges and acquired in-process research and development resulting from two acquisitions . we expect to continue to incur losses in the future as we continue our research and development efforts and seek approval from various regulatory agencies for our product candidates , but there can be no assurance that we will obtain approval for our product candidates and achieve revenues from product sales . -45- in march 2008 , we acquired all of the stock of ercole biotechnology , inc. , or ercole , in exchange for 5,811,721 shares of our common stock , which was valued at approximately $ 8.4 million , and the assumption of approximately $ 1.8 million in liabilities of ercole . we also issued warrants to purchase our common stock ( also classified as equity ) , which were valued at $ 437,000 , in exchange for certain outstanding warrants issued by ercole . in december 2011 , we restructured our operations by reducing our workforce by 35 employees , or 28 % . restructuring charges totaling $ 1.1 million were recorded in 2011 and included severance and related costs . the charge included approximately $ 0.5 million to research and development expense and approximately $ 0.6 million to general and administrative expense . the restructuring was completed by january 31 , 2012 and all severance costs are expected to be paid by july 31 , 2012. as of december 31 , 2011 , we had cash and cash equivalents of $ 39.9 million and we anticipate receiving continued funding from the u.s. government to pursue the development of our therapeutics against ebola and marburg . combined together , we believe these sources provide us with sufficient cash to fund operations at least through the following 12 months . in addition , we are likely to pursue additional funding through public or private financings and cash generated from establishing collaborations or licensing our technology to other companies . should our funding from the u.s. government cease or be delayed , it would have a significant negative impact on our financial condition and on this guidance and we would likely be forced to significantly curtail our research and development efforts . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with u.s. government sponsored programs , and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenues or profitable operations . u.s. government contracts in the periods presented , nearly all of the revenue we generated was derived from research contracts with and grants from the u.s. government . as of december 31 , 2011 , we had substantially completed all of our contracts with the u.s. government except for the july 2010 agreement for the development of therapeutics against ebola and marburg . pursuant to this agreement , as of december 31 , 2011 , we are currently entitled to receive up to $ 126.5 million of which $ 52.7 million has been recognized as revenue . in addition , if the u.s. government elects to exercise all its options under the agreement , an additional $ 161.5 million in funding is available . the following table sets forth the revenue from each of our contracts with the u.s. government and other revenue for the years ended december 31 , 2011 , 2010 and 2009. replace_table_token_5_th -46- the following is a description of each of our significant u.s. government contracts and grants . story_separator_special_tag million or decreased up to $ 1.0 million , respectively , with such difference reflected in our statement of operations . see note 9warrants of the audited financial statements included elsewhere in this annual report on form 10-k for a further discussion of warrants . results of operations for the years ended december 31 , 2011 , 2010 and 2009 the following table sets forth selected consolidated statements of operations data for each of the periods indicated : summary of results for fiscal years 2011 , 2010 and 2009 replace_table_token_8_th -51- revenue revenue for 2011 increased by $ 17.6 million , or 60 % , compared to 2010. the increase was primarily due to the 2010 ebola and marburg contract we received in july 2010 , which contributed revenue of $ 42.9 million in 2011 , an increase of $ 33.1 million over the prior year . this increase was partially offset by decreases in revenue on contracts we completed during 2011 , including $ 10.0 million from the may 2009 and june 2010 h1n1 agreements , $ 1.2 million from the qtdp grants and a $ 3.7 million decrease for the 2006 ebola , marburg and junín contracts . revenue for 2010 increased by $ 11.8 million , or 67 % , compared to 2009 due to the increase from the ebola and marburg contract of $ 9.8 million , increases in revenue from the h1n1 contracts of $ 12.3 million , and an increase of $ 1.2 million from the qtdp grants . these increases were partially offset by a $ 9.1 million decrease in revenue from the 2006 ebola , marburg and junín contract and a $ 2.4 million decrease in children 's national medical center contract related to dmd . research and development expenses research and development expenses for 2011 increased by $ 30.9 million , or 86 % , compared to 2010 due primarily to a $ 22.8 million increase in costs related to the july 2010 ebola and marburg contract , a $ 6.4 million increase in costs for our proprietary dmd program that is in phase ii clinical trials , a $ 4.8 million increase for proprietary research and development and a $ 3.9 million increase from manufacturing activities . these increases were partially offset by a $ 5.0 million decrease in costs related to the h1n1 contracts completed in 2011 and a $ 2.0 million decrease related to the 2006 ebola , marburg and junín contract , which was substantially completed in 2010. research and development expenses for 2010 increased by $ 11.6 million , or 47 % , compared to 2009 due primarily to a $ 5.6 million increase in costs related to the july 2010 ebola and marburg contract and a $ 4.2 million increase in costs related to the june 2010 h1n1 government contract . both of these contracts were new in 2010. additionally , overall research and development spending increased by $ 4.6 million and expenditures on the 2009 h1n1 government contract increased $ 1.5 million . these increases were offset by a $ 4.3 million decline in spending related to the 2006 ebola , marburg and junín contracts . general and administrative expenses general and administrative expenses for 2011 increased by $ 1.7 million , or 12 % , compared to 2010. this increase was due primarily to an increase of $ 1.4 million in personnel related costs and $ 1.1 million in professional consulting costs . legal fees and employee severance costs decreased by approximately $ 0.5 million each while facility costs also increased by $ 0.2 million . general and administrative expenses for 2010 increased by $ 5.7 million , or 65 % , compared to 2009. this significant increase in 2010 was due to $ 2.6 million in severance costs and stock compensation expense related to the departure in april 2010 of our former chief executive officer and an increase of $ 2.0 million in employee costs due to the july 2010 ebola and marburg contract and the h1n1 contracts . other increases included legal costs of $ 0.9 million , facilities expense of $ 0.4 million for the addition of our new bothell , washington facilities , and a $ 0.4 million loss on the write down of the property held for sale . these increases were partially offset by a $ 0.6 million decrease in professional consulting costs . interest income ( expense ) and other , net the increase in interest income ( expense ) and other , net for 2011 compared to 2010 was primarily due to increased interest income on invested cash . the increase in interest income ( expense ) and other , net for 2010 compared to 2009 was attributable to increased interest income on invested cash of $ 0.1 million and $ 0.1 million from increased rental income from -52- the sublease of excess space in our corvallis , oregon facility . additionally , these increases in income were offset by decreases of $ 0.5 million in patent abandonments and impairment of property held for sale that occurred in 2009. decrease ( increase ) on warrant valuation in 2011 , we recognized $ 33.0 million of other income due to the reduction in the fair value of our outstanding warrants that are classified as liabilities on our consolidated balance sheet . in 2010 , we recognized $ 11.5 million of other expense due to the increase in the fair value of the outstanding warrants on our consolidated balance sheet . the change in fair value of our warrant liability is primarily attributable to the change in our stock price . net loss the decrease in net loss of $ 29.9 million , or 93 % , for 2011 compared to 2010 was primarily attributable to a $ 44.9 million increase in other income resulting from a decrease in the fair value of our outstanding warrants offset by an increase in operating loss of $ 15.0 million

